New York, New York 10021

  • Breast Cancer


RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of gemcitabine in treating women with metastatic breast cancer previously treated with doxorubicin and paclitaxel.

Study summary:

OBJECTIVES: - Determine the objective response rate to gemcitabine in women with metastatic breast cancer previously treated with two to four chemotherapy regimens, including doxorubicin and paclitaxel. - Characterize the nature of toxicity of gemcitabine in this patient population. - Determine the response duration to gemcitabine in this patient population. OUTLINE: Patients receive gemcitabine IV over 30 minutes once weekly for 3 consecutive weeks (days 1, 8, and 15) followed by 1 week of rest. Treatment continues every 4 weeks in the absence of disease progression or unacceptable toxic effects. Patients are followed until death. PROJECTED ACCRUAL: A total of 14-30 patients will be accrued for this study within 13 months.


DISEASE CHARACTERISTICS: - Histologically confirmed metastatic breast cancer - Bidimensionally measurable disease - No bone scan abnormalities alone - Lytic lesions in conjunction with bone scan abnormalities allowed - No pure blastic bone metastases - No pleural or peritoneal effusions - No previously irradiated lesions - Must have received 2-4 prior chemotherapy regimens, including paclitaxel and doxorubicin, for breast cancer - Brain metastases allowed if other measurable disease exists - No uncontrolled or life threatening brain lesions - No carcinomatous meningitis - Hormone receptor status: - Not specified PATIENT CHARACTERISTICS: Age: - 18 and over Sex: - Female Menopausal status: - Not specified Performance status: - Karnofsky 60-100% Life expectancy: - Not specified Hematopoietic: - Granulocyte count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 Hepatic: - AST/ALT no greater than 5 times upper limit of normal Renal: - Calcium no greater than 11.0 mg/dL Other: - Not pregnant - Negative pregnancy test - No history of other malignancy except carcinoma in situ of the cervix or curatively treated nonmelanoma skin cancer - No other serious medical illnesses, including severe infection and severe malnutrition PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - See Disease Characteristics - At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas and mitomycin) and recovered - No other concurrent chemotherapy Endocrine therapy: - Prior hormonal therapies for stage IV disease and/or adjuvant therapy allowed - At least 3 weeks since prior hormonal therapy Radiotherapy: - See Disease Characteristics - No prior radiotherapy to greater than 30% of the marrow bearing bone - At least 4 weeks since prior radiotherapy and recovered - No concurrent radiotherapy to the only measurable lesion Surgery: - Recovered from prior surgery - No concurrent surgery to the only measurable lesion Other: - No concurrent nonprotocol treatment



Primary Contact:

Study Chair
Violante E. Currie, MD
Memorial Sloan-Kettering Cancer Center

Backup Contact:


Location Contact:

New York, New York 10021
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: June 21, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.